Flaghship Pioneering, a Cambridge, MA-based biotechnology company that invents and builds platform companies, announced the promotions of four new Origination Partners: Kyle Chiang, Molly Gibson, Armen Mkrtchyan, and Jacob Rubens.
- Kyle Chiang leads a team of entrepreneurs responsible for originating and growing new companies. Since joining Flagship, Chiang has held numerous operational roles at Flagship companies including Chief Scientific Officer of Senda Biosciences (now Sail Biomedicines) and Chief Operating Officer of Montai. Prior to joining Flagship in 2021, he served as Chief Operating Officer at LogicBio Therapeutics, where he led regulatory engagements to open an IND for a genome editing platform, supported multiple financing rounds including the company’s IPO, and facilitated business development engagements that led to multiple research and strategic collaborations. He was previously with aTyr Pharma holding roles across discovery and clinical teams, serving as a program lead and supporting the intellectual property portfolio strategy.
- Molly Gibson works to found and grow companies at the intersection of biology and machine learning including Generate: Biomedicines, Tessera Therapeutics, and Cobalt Biomedicines (merged into Sana Biotechnology). She currently serves as co-founder and chief innovation officer of Generate Biomedicines. Prior to joining Flagship in 2017, Gibson led computational biology at Kaleido Biosciences.
- Armen Mkrtchyan leads Pioneering Intelligence, an initiative to institutionalize and expand the use of Artificial Intelligence (AI) across Flagship and portfolio companies, and to help drive Flagship’s efforts in AI research to identify innovation platforms in human health and sustainability. Mkrtchyan joined Flagship from McKinsey & Company where he was an Associate Partner. He led large corporate transformations, client development efforts, and engagements on strategy and operations with a focus on the impact of AI in the automotive, aerospace, and high-tech/electronics sectors. Mkrtchyan was previously an Assistant Professor at the American University of Armenia and established the Entrepreneurship and Product Innovation Center (EPIC), an incubation center to further the knowledge and practice of entrepreneurship in Armenia.
- Jacob (Jake) Rubens, Ph.D., leads a venture-creation team that founds and grows companies based on new biotechnology. He is a co-founder of Quotient Therapeutics, Tessera Therapeutics, and Sana Biotechnology, and launched Kaleido Biosciences. Rubens is the President of Quotient and Chief Innovation Officer and founding Chief Scientific Officer at Tessera, where he led research from 2018 through 2021. Previously, Rubens was the Head of Innovation at Cobalt Biomedicine, where he co-invented and developed the company’s Fusosome platform prior to its merger with Sana Biotechnology.
Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $70 billion in aggregate value. To date, it has deployed over $3.6 Billion in capital toward the founding and growth of its pioneering companies alongside more than $27 Billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 40 companies, including Denali Therapeutics (NASDAQ: DNLI), Foghorn Therapeutics (NASDAQ: FHTX), Generate:Biomedicines, Inari, Indigo Agriculture, Moderna (NASDAQ: MRNA), Omega Therapeutics (NASDAQ: OMGA), Sana Biotechnology (NASDAQ: SANA), Seres Therapeutics (NASDAQ: MCRB) and Tessera Therapeutics.